{"id":949744,"date":"2026-04-08T07:03:09","date_gmt":"2026-04-08T11:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/"},"modified":"2026-04-08T07:03:09","modified_gmt":"2026-04-08T11:03:09","slug":"united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/","title":{"rendered":"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure"},"content":{"rendered":"

<\/p>\n

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP<\/i>\u00ae<\/sup> for Treatment of Acute Liver Failure<\/b><\/p>\n

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE<\/a>)–
\nUnited Therapeutics Corporation (Nasdaq: UTHR<\/b>), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA<\/b>) has granted Regenerative Medicine Advanced Therapy (RMAT<\/b>) designation to the company\u2019s investigational miroliverELAP<\/i>\u00ae<\/sup>, an external liver assist product.<\/p>\n

\nDeveloped by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP<\/i> consists of an external blood circuit and a single-use bioengineered liver sustained outside of the human body to provide temporary liver support to ALF patients. The bioengineered liver is manufactured by seeding a decellularized porcine liver scaffold with allogeneic human endothelial cells and human liver cells isolated from donated human livers. The donated human livers are not suitable for transplantation and are provided by organ procurement organizations.<\/p>\n

\nIn January, United Therapeutics announced<\/a> positive results from its phase 1 study of miroliverELAP <\/i>in patients with acute forms of liver failure, acute-on-chronic liver failure, and severe acute alcoholic hepatitis, collectively called acute liver failure (ALF<\/b>). Full study results will be published in the second half of 2026. miroliverELAP<\/i> is investigational and is not approved for any use in any country. In addition to miroliverELAP<\/i>, United Therapeutics and Miromatrix are developing mirokidney\u00ae<\/sup>, a fully transplantable bioengineered kidney, utilizing the same decellularization and seeding technology used in miroliverELAP<\/i>.<\/p>\n

\nThe FDA\u2019s RMAT designation is a specialized program created to accelerate the development and regulatory review of promising regenerative medicine therapies that target serious or life-threatening diseases with unmet medical needs while maintaining rigorous safety and efficacy standards. To receive RMAT designation, a therapy must demonstrate preliminary clinical evidence of potential efficacy in treating, modifying, reversing, or curing such conditions. Once designated, sponsors receive intensive FDA guidance throughout the development process, including advice on efficient study design, surrogate endpoints, and pathways to accelerated approval. The designation also provides significant regulatory advantages, such as eligibility for priority review, rolling review of Biologics License Application materials, and enhanced organizational commitment from the FDA to expedite the overall development and approval timeline.<\/p>\n

\n\u201cReceiving this designation from the FDA highlights both the critical unmet need we are addressing and the promising potential of miroliverELAP<\/i> as a novel therapeutic option,\u201d said Jeff Ross, Ph.D.<\/b>, President of Miromatrix. \u201cWe look forward to continuing our collaborative exchange with the FDA as we advance the clinical development of miroliverELAP<\/i> for patients with acute liver failure.\u201d<\/p>\n

\nALF, a devastating condition that affects thousands of patients each year, is characterized by a rapid loss of liver function in a matter of days or weeks. Approximately 45% of ALF patients will experience spontaneous recovery, while 25% will receive a liver transplant, the only effective ALF treatment. Approximately 30% of ALF patients will die because they are ineligible for a liver transplant or are unable to receive one in time due to the rapid onset of the disease and the drastic shortage of transplantable organs.1<\/sup><\/p>\n

\nUnited Therapeutics\u2019 organ and organ alternative manufacturing efforts consist of three platforms \u2014 xenotransplantation, allogeneic regenerative medicine, and autologous regenerative medicine \u2014 encompassing four different organs: hearts, kidneys, livers, and lungs. These programs are intended to address the ongoing shortage of transplantable organs for patients with end-stage organ disease.<\/p>\n

About United Therapeutics<\/b><\/p>\n

\nFounded by CEO Martine Rothblatt to discover a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com<\/a> and follow us on LinkedIn<\/a>, Facebook<\/a>, and Instagram<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nStatements included in this press release that are not historical in nature are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning: the promising potential of miroliverELAP<\/i> as a novel therapeutic option; the timing of our regulatory efforts with respect to miroliverELAP<\/i>, including the potential acceleration of such efforts afforded by RMAT designation; our clinical development plans for miroliverELAP<\/i>; our plans to publish the results of our phase 1 study of miroliverELAP<\/i>; United Therapeutics\u2019 broader organ and organ alternative manufacturing program; and our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 8, 2026, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason<\/p>\n

\nMIROLIVERELAP and MIROKIDNEY are trademarks of United Therapeutics Corporation and its subsidiaries.<\/p>\n

1<\/sup> Lee, W. M., Squires, R. H., Jr, Nyberg, S. L., Doo, E., & Hoofnagle, J. H. (2008). Acute liver failure: Summary of a workshop. Hepatology (Baltimore, Md.)<\/i>, 47<\/i>(4), 1401\u20131415. https:\/\/doi.org\/10.1002\/hep.22177<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260408473035\/en\/<\/a><\/span><\/p>\n

Investor Inquiries
\n<\/b>
https:\/\/ir.unither.com\/contact-ir<\/a><\/p>\n

Media Inquiries
\n<\/b>
communications@unither.com<\/a><\/p>\n

KEYWORDS:<\/b> North Carolina Maryland United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Cardiology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company\u2019s investigational miroliverELAP\u00ae, an external liver assist product. Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood circuit and a single-use bioengineered liver sustained outside of the human body to provide temporary liver support to ALF patients. The bioengineered liver is manufactured by seeding a decellularized porcine liver scaffold with allogeneic human endothelial cells and human … <\/p>\n

Continue reading “United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949744","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nUnited Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company\u2019s investigational miroliverELAP\u00ae, an external liver assist product. Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood circuit and a single-use bioengineered liver sustained outside of the human body to provide temporary liver support to ALF patients. The bioengineered liver is manufactured by seeding a decellularized porcine liver scaffold with allogeneic human endothelial cells and human … Continue reading "United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T11:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure\",\"datePublished\":\"2026-04-08T11:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/\"},\"wordCount\":1019,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/\",\"name\":\"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-04-08T11:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/","og_locale":"en_US","og_type":"article","og_title":"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure - Market Newsdesk","og_description":"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company\u2019s investigational miroliverELAP\u00ae, an external liver assist product. Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood circuit and a single-use bioengineered liver sustained outside of the human body to provide temporary liver support to ALF patients. The bioengineered liver is manufactured by seeding a decellularized porcine liver scaffold with allogeneic human endothelial cells and human … Continue reading \"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T11:03:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure","datePublished":"2026-04-08T11:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/"},"wordCount":1019,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/","name":"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-04-08T11:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408473035r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/united-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-miroliverelap-for-treatment-of-acute-liver-failure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP\u00ae for Treatment of Acute Liver Failure"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949744"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949744\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}